CORESTEM Inc (166480) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of CORESTEM Inc stock KRW 1,233, price KRW 1,363, that is 9.6% below the price, quality 14 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
CORESTEM Inc
166480 · KQExpensive (fair value 10% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range 1,060 KRW – 19,338 KRW · fair‑value band 924.41 KRW – 1,541 KRW · the 1,363 KRW price screens above the 1,233 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether CORESTEM is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea.
Show moreShow less
It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases.
The company has a strategic partnership with ATG Lifetech to deliver precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures. The company was formerly known as Corestem, Inc. CORESTEMCHEMON Inc. was founded in 2003 and is based in Seongnam-si, South Korea.
Stock analysis
CORESTEM Inc (166480) currently trades at 1,363 KRW, while our estimate is 1,233 KRW, 10% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 924.41 KRW (bear) to 1,541 KRW (bull), the price of 1,363 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 14/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
CORESTEM Inc reported revenue of 20.2B KRW in FY2025 versus 30.2B KRW in FY2021, a compound −9.6%/yr. Reported net income was −26.8B KRW in FY2025.
Key figures
Market cap 66.8B KRW (≈ $50.2M) Micro · P/S ratio 4.57 · EPS (TTM) −578.16 KRW · Net margin −133% · Return on equity −62.0% · Return on assets (EBIT) −16.2% (5-year average) · Operating margin −79.3% · Revenue (TTM) 18.3B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 72% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −10%, 166480 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare CORESTEM Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $945.53 | $1,275 | +35% | vs 166480 |
| Vertex Pharmaceuticals Incorporated VRTX | $536.45 | $587.62 | +10% | vs 166480 |
| Samsung Biologics Co 207940 | 1,375,000 KRW | 1,502,600 KRW | +9% | vs 166480 |
| argenx SE ARGX | $941.25 | $908.40 | −3% | vs 166480 |
| CSL Limited CSL | A$199.85 | A$186.49 | −7% | vs 166480 |
| Moderna, Inc MRNA | $196.79 | $135.64 | −31% | vs 166480 |
| BeOne Medicines AG 6160 | HK$242.60 | HK$152.92 | −37% | vs 166480 |
| Revolution Medicines, Inc RVMD | $159.82 | $83.12 | −48% | vs 166480 |
| Celltrion, Inc 068270 | 215,000 KRW | 74,945 KRW | −65% | vs 166480 |
| Royalty Pharma plc RPRX | $68.67 | $19.01 | −72% | vs 166480 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is CORESTEM Inc (166480) overvalued or undervalued?
What is the fair value of 166480?
What is the quality score of 166480?
What is the price target for CORESTEM Inc (166480)?
What is the CORESTEM Inc stock forecast for 2026?
What is the revenue of CORESTEM Inc (166480)?
What is the intrinsic value of CORESTEM Inc (166480)?
Is CORESTEM Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 166480?
How much is CORESTEM Inc worth?
What do the bullish and bearish scenarios say about 166480?
How solid is the balance sheet of CORESTEM Inc (166480)?
How far is 166480 from its 52-week high?
Which stocks are comparable to CORESTEM Inc?
Is CORESTEM Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of CORESTEM Inc (166480)?
What should I pay attention to with CORESTEM Inc right now?
Key figures of CORESTEM Inc
How large is the market capitalisation of CORESTEM Inc (166480)?
What is the P/S ratio of CORESTEM Inc (166480)?
What are the earnings per share of CORESTEM Inc (166480)?
What is the net margin of CORESTEM Inc (166480)?
What is the return on equity of CORESTEM Inc (166480)?
What is the EBIT return on assets of CORESTEM Inc (166480)?
What is the operating margin of CORESTEM Inc (166480)?
How fast is revenue growing at CORESTEM Inc (166480)?
How much free cash flow does CORESTEM Inc (166480) generate?
How much net debt does CORESTEM Inc (166480) carry?
Watch CORESTEM Inc in the live analysis
One click puts CORESTEM Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.